Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence

Open Access Journal of Urology

Volumn 4, Issue 1, 2012, Pages 49-56

  Shore, Neal D ^a   Fernandez, Cecilia A ^b   Shuber, Anthony P ^b  

^a Carolina Urologic Research Center   (United States)

^b Predictive Biosciences Inc   (United States)

Author keywords

FGFR3; Matrix metalloproteinase 2; NID2; Recurrent bladder cancer; VIM

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; GELATINASE A; NIDOGEN 2 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

AGED; ARTICLE; ASSAY; BLADDER CANCER; CANCER RISK; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MULTICENTER STUDY; NIDOGEN 2 GENE; NON INVASIVE MEASUREMENT; OBSERVATIONAL STUDY; PATIENT MONITORING; PREDICTIVE VALUE; RECURRENT CANCER; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; URINALYSIS; VIMENTIN GENE;

EID: 84868104318     PISSN: None     EISSN: 11791551     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Gazzaniga P, Gradilone A, de Berardinis E, etal. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol. February 28, 2012;23(9):2352-2356.
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164(3 Pt 1):680-684.
4. Sugano K, Kakizoe T. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat Clin Pract Urol. 2006;3(12):642-652.
5. Babjuk M, Oosterlinck W, Sylvester R, etal. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997-1008.
6. Scher H, Bahnson R, Cohen S, etal. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park). 1998;12(7A):225-271.
7. Brausi M, Witjes JA, Lamm D, etal. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(6):2158-2167.
8. Fenlon HM, Bell TV, Ahari HK, Hussain S. Virtual cystoscopy: early clinical experience. Radiology. 1997;205(1):272-275.
9. Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology. 2008;71(1):131-135.
10. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol. 2004;14(5):277-286.
11. Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP. A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. Research and Reports in Urology. 2012;4:17-26.
12. Karnes RJ, Fernandez CA, Shuber AP. A non-invasive multi-analyte urine based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clinic Proc. 2012;87(9):835-842.
13. Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology. 2006;67(3 Suppl 1):48-54.
14. Fernandez CA, Wszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP. A novel approach to using matrix metalloproteinases for bladder cancer. J Urol. 2009;182(5):2188-2194.
15. Costa VL, Henrique R, Danielsen SA, etal. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010;16(23):5842-5851.
16. Kompier LC, van der Aa MN, Lurkin I, etal. The development of multiple bladder tumour recurrences in relation to the FGFR3mutation status of the primary tumour. J Pathol. 2009;218(1):104-112.
17. van Oers JM, Lurkin I, van Exsel AJ, etal. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005; 11(21):7743-7748.
18. van Oers JM, Zwarthoff EC, Rehman I, etal. FGFR3mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650-657.
19. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61(4):1265-1268.
20. Zuiverloon TC, van der Aa MN, van der Kwast TH, etal. Fibroblast growth factor receptor 3mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16(11):3011-3018.
21. Horstmann M, Pastchan O, Hennenlotter J, et al. Combinations of urine-based tomour markers in bladder cancer surveillance. Scand J Urol Nephrol. 2009;43:461-466.
22. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer. 1999;87(3):118-128.
23. Hanno PM, Burks DA, Clemens JQ, etal. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162-2170.
24. Chamie K, Saigal CS, Lai J, etal. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117(23):5392-5401.